ROCKVILLE, Md., May 10, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the Gene Therapy and Gene Editing panel discussion at the Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17, 2017 at 1:40 p.m. PT at the Encore Wynn in Las Vegas, NV. In addition, REGENXBIO senior management will be holding one-on-one meetings at the conference.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Heather Savelle, 646-395-3734
Adam Pawluk, 202-591-4063